Tempus AI, Inc. (NASDAQ:TEM) Given Consensus Recommendation of “Hold” by Analysts

Shares of Tempus AI, Inc. (NASDAQ:TEM) have been assigned a consensus rating of “Hold” from the fifteen research firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $68.6429.

Several research firms recently commented on TEM. JPMorgan Chase & Co. cut their target price on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating for the company in a research note on Wednesday, February 25th. Wolfe Research assumed coverage on shares of Tempus AI in a research note on Tuesday, June 2nd. They set a “peer perform” rating for the company. Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. BTIG Research reissued a “buy” rating and issued a $80.00 price target on shares of Tempus AI in a report on Monday, June 1st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $75.00 price target on shares of Tempus AI in a report on Monday, June 1st.

Insider Transactions at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 8,703 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $383,541.21. Following the sale, the executive vice president owned 128,215 shares of the company’s stock, valued at $5,650,435.05. The trade was a 6.36% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Ryan M. Bartolucci sold 4,116 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $181,392.12. Following the completion of the sale, the chief accounting officer directly owned 74,041 shares in the company, valued at $3,262,986.87. This trade represents a 5.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 558,557 shares of company stock worth $26,611,939. 24.26% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Tempus AI by 22.1% during the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after purchasing an additional 1,706,837 shares during the period. Krane Funds Advisors LLC lifted its position in Tempus AI by 218.2% during the 3rd quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock valued at $2,427,000 after purchasing an additional 19,358 shares during the period. Aberdeen Group plc lifted its position in Tempus AI by 64.2% during the 4th quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock valued at $15,530,000 after purchasing an additional 102,878 shares during the period. Pictet Asset Management Holding SA lifted its position in Tempus AI by 291.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock valued at $2,948,000 after purchasing an additional 36,096 shares during the period. Finally, Bogart Wealth LLC lifted its position in Tempus AI by 365,087.5% during the 4th quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock valued at $3,450,000 after purchasing an additional 58,414 shares during the period. Institutional investors own 24.22% of the company’s stock.

Tempus AI Price Performance

NASDAQ:TEM opened at $52.32 on Tuesday. The stock has a market cap of $9.40 billion, a P/E ratio of -30.42 and a beta of 3.64. Tempus AI has a one year low of $41.73 and a one year high of $104.32. The company has a fifty day moving average price of $49.42 and a 200 day moving average price of $56.51. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15.

Tempus AI (NASDAQ:TEM) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. The firm had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The business’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.24) EPS. Analysts anticipate that Tempus AI will post -1.35 earnings per share for the current year.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.